Hyperbaric Oxygen Therapy

Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.

A study published recently in Nature found that hyperbaric oxygen therapy led to positive results for cognition and functionality for those with long COVID.

Hyperbaric oxygen therapy improved pain symptoms, quality of life and social and emotional function in adults with fibromyalgia after traumatic brain injury compared with pharmacologic intervention, according to research in PLOS One.

Results of a randomized, double-blind trial showed that hyperbaric oxygen therapy improved cognitive and behavioral function in children experiencing persistent post-concussion syndrome, as published in Scientific Reports.

Last week, Healio provided coverage of the Crohn’s and Colitis Congress.

DENVER — Hyperbaric oxygen therapy yielded a clinical response rate of 87% among patients with fistulizing Crohn’s disease with few adverse events, according to systematic review data presented at the Crohn’s and Colitis Congress.

Hyperbaric oxygen was safe and effective for treating patients with COVID-19 and severe hypoxemia, according to new findings published in Emergency Medicine Journal.

Hyperbaric oxygen therapy safely relieved symptoms of late radiation cystitis among patients who received radiotherapy for cancer in the pelvic region, according to results of the randomized phase 2/phase 3 RICH-ART trial published in The Lancet Oncology.